A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2

John Hamilton *, Iain Jones, Rajeev Srivastava, Peter Galloway

Biochemistry Department, Yorkhill Hospital, Yorkhill, Glasgow G3 8SJ, United Kingdom

ARTICLE INFO

ABSTRACT

Background: Cholesterol ester storage disease (CESD) and Wolman Disease (WD) are due to deficiency of lysosomal acid lipase (LAL). A new method is described for the measurement of LAL in dried blood spots (DBS) using Lalistat 2 an inhibitor of LAL.
Methods: LAL activity in DBS extracts was measured using the substrate 4-methylumbelliferyl palmitate. LAL activity was determined by measuring total lipase activity and lipase activity in the presence of Lalistat 2. The specificity of Lalistat 2 was investigated using human recombinant LAL (hrLAL) and human pancreatic lipase (hPL).
Results: Lalistat 2 inhibited hrLAL with 1% residual activity at 1 μM inhibitor but had no effect on hPL up to 10 μM. LAL activity in DBS samples obtained from normal controls ($n = 140$) was 0.50–2.30 nmol/punch/h and in patients with CESD was <0.03 nmol/punch/h ($n = 11$). Activity in carriers showed intermediate activity: 0.15–0.40 nmol/punch/h ($n = 15$).
Conclusions: Measurement of LAL using DBS is made difficult by the presence of other lipases in whole blood. Lalistat 2 is a specific inhibitor of LAL which allows the determination of LAL in DBS. Results show the method differentiates clearly between normal controls, carriers and affected cases.

© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.

1. Introduction

Wolman disease (WD) and Cholesterol ester storage disease (CESD) are lysosomal storage disorders due to deficiency of the enzyme lysosomal acid lipase (LAL; EC 3.1.1.13). The enzyme cleaves both cholesterol esters and triglycerides under acidic conditions. WD is the severe form of the disorder presenting in infancy with hepatospleno...

...premature cardiovascular disease and non alcoholic steatohepatitis (NASH) [1]. The incidence of CESD is estimated from genetic studies to be 1:40,000 [2], though clinically far fewer cases than this are identified. The incidence of WD is estimated at approximately 1:500,000 [3]. There is no specific treatment for WD with death normally occurring by 3 to 6 months. Current therapy for CESD consists of a low-fat diet and lipid-lowering drugs such as statins and colestyramine [4]. There is interest in the potential use of recombinant human LAL for enzyme replacement therapy (ERT) in LAL deficient patients [5] and the efficacy of recombinant human LAL has been demonstrated in an LAL-null mouse model [6].

A method has been adapted for the measurement of LAL in DBS based on the method of Guy et al. [7] applied originally to the measurement

of LAL in fibroblasts. LAL is measured using the fluorimetric substrate 4-methylumbelliferyl palmitate (4 mU palmitate) with cardiolipin present as an activator of LAL. The presence of other forms of lipase in whole blood [8] will interfere with the measurement of LAL. Lalistat 2 is a specific inhibitor of LAL [9,10] and by measuring total lipase activity and lipase activity in the presence of Lalistat 2 LAL can be determined in DBS.

...thiadiazole carba-... Both compounds were assessed in our assay and Lalistat 2 found to give marginally higher activity for LAL at the same concentration of inhibitor. Therefore Lalistat 2 was selected as the inhibitor of choice in the assay.

2. Materials and methods

2.1. Samples

A reference range was established using anonymised ethylenediaminetetraacetic acid (EDTA) blood obtained from samples submitted to our laboratory for routine diagnostic testing. Blood was spotted on to filter paper (Whatman grade 903 Schleicher & Schuell) on the day of venepuncture and allowed to dry overnight at room temperature. Samples were stored double-bagged with dessicant at −20 °C and analysed within 1 week of storage. DBS samples from 11 patients with CESD and 15 carriers were provided by Synageva BioPharma

---

(Lexington, Massachusetts, USA). Samples were obtained following written, informed consent.

2.2. Sample collection and storage for stability study

EDTA blood obtained from 3 healthy adult controls was used to prepare DBS samples. Samples were stored at room temperature, 4 °C and −20 °C doubled-bagged with dessicant for up to 100 days.

2.3. Chemicals and reagents

Cardiolipin (sodium salt, bovine), sodium acetate (trihydrate), 4-methylumbelliferone (4 mU), dimethylsulfoxide (DMSO), human serum albumin (HSA) and hPL were obtained from Sigma–Aldrich Company Ltd. (Dorset, England). 4 mU palmitate was from Apollo Scientific Ltd (Stockport, Cheshire, UK). Mercuric chloride was from Merck KGaA (Darmstadt, Germany). Triton X-100 was from Koch Light (Cambridge, Cambridgeshire, UK). Lalistat 1 and Lalistat 2 were donated by Dr. P Helquist, Chemical Tools (South Bend, IN, USA) [10]. Recombinant human LAL was supplied by Synageva Biopharma (Lexington, Massachusetts, USA).

A buffer solution was prepared using 0.15 M acetate buffer pH 4.0, 1.0% Triton X-100. 14 ml buffer was retained at 37 °C (water bath) and to this was added 1.0 ml 0.5% (w/v) cardiolipin in methanol and 400 µl 13.3 mM 4 mU palmitate in DMSO (heated to 55 °C to dissolve) to give substrate-buffer solution. 30 µM Lalistat 2 was prepared fresh each time by diluting 200 µM Lalistat 2 (in DMSO) with distilled water. A 30 µM working solution of Lalistat 1 was prepared from 200 µM stock in the same way.

2.4. Sample extraction and assay procedure

3.2 mm spots were extracted with 200 µl water by mixing for 1 h at room temperature. The assay was performed using 96 well plates (Optiplate 96, Perkin Elmer, Cambridge, Cambridgeshire, UK). Uninhibited and inhibited reactions were each performed in duplicate requiring 4 wells per sample. 40 µl sample was added to each well and 10 µl 30 µM Lalistat 2 was added for inhibited reaction. 10 µl water was added to corresponding wells for uninhibited reaction. The plate was sealed with adhesive aluminium film and placed on a plate shaker for 2 min followed by pre-incubation for 10 min at 37 °C. 150 µl substrate-buffer solution (retained at 37 °C until use) was added to all wells and the plate re-sealed. The plate was shaken for a further 2 min and incubated at 37 °C for 3 h. Reaction was stopped by adding 100 µl 15 mM HgCl2 to all sample wells.

A 0–2.5 nmol 4 mU standard curve was made by diluting 0.5 mM 4 mU standard with water (200 µl per well) and adding 100 µl 15 mM mercuric chloride to each well. Fluorescence was measured using a Wallac Victor 2 1420 Multilabel Counter (Perkin Elmer, Cambridge, Cambridgeshire, UK) (excitation 355 nm, emission 460 nm). The instrument was programmed to read the plates twice with a 5 minute interval between readings to allow dark adaptation of 4 mU. The second reading was used to determine results. LAL activity was determined by subtracting activity in the inhibited reaction from uninhibited reaction (total lipase) and calculated as nmol/punch/h.

3. Results

The effect of Lalistat 2 as an inhibitor of LAL was assessed by incubating Lalistat 2 with rhLAL (0.002 U/ml). Lalistat 2 was shown to inhibit rhLAL with only 1% residual enzyme activity remaining at a concentration of 1 µM inhibitor (Fig. 1). The effect of Lalistat 2 on hPL (6 U/ml) was assessed and found to have no effect on enzyme activity up to 10 µM inhibitor (Fig. 2).

The effect of Lalistat 1 and Lalistat 2 were compared by assessing enzyme activity using a pooled DBS extract from the same sample.


Fig. 1. Inhibitory effect of Lalistat 2 on rhLAL. Final concentration of rhLAL 0.002 U/L. Enzyme pre-incubated with inhibitor for 10 min. Incubation time 10 min.


Fig. 2. Inhibitory effect of Lalistat 2 on human pancreatic lipase. Final concentration 6 U/ml. Enzyme pre-incubated with inhibitor for 10 min. Incubation time 2 h.

Inhibitors were present at concentrations from 0.5 to 5.0 µM (Fig. 3). Activity derived for LAL in DBS extract was higher with Lalistat 2 than Lalistat 1 at all concentrations of inhibitor (mean difference 7%) demonstrating more effective inhibition of LAL with Lalistat 2 than Lalistat 1. Optimal inhibition is achieved at a concentration 1.5 µM for both inhibitors.

The effect of pre-incubating enzyme with inhibitor was assessed by incubating rhLAL with Lalistat 2 for up to 15 min before adding substrate. Lalistat 2 was present at 0.1 to 10 µM. The degree of inhibition was dependant on both the concentration of inhibitor and pre-incubation time (Fig. 4). A pre-incubation time of 5 min was the minimum time required for optimal inhibition with 1.0 µM Lalistat 2.

Linearity of the method was assessed by incubating for up to 5 h and was shown to be adequate up to 3 h. Within-run coefficient of variation


**Fig. 3.** Activity derived for LAL with Lalistat 1 and Lalistat 2 using pooled DBS extract.

Fig. 4. Lalistat 2 (0.1–10 μM) pre-incubated with human recombinant LAL from 0 to 15 min.

Fig. 6. LAL activity in 140 normal controls, 11 LAL deficient patients and 15 carriers. Limit of detection = 0.02 nmol/punch/h.

(CV) was 5.0% for a control with normal LAL activity ($n = 20$) and 4.2% for a control with intermediate LAL activity ($n = 20$). Between-run CV was 5.6% for normal control ($n = 21$) and 11.0% for intermediate control ($n = 21$). The limit of detection was 0.01 nmol/punch/h and limit of quantification was 0.02 nmol/punch/h.

Stability of LAL in DBS stored at different temperatures was assessed by measuring enzyme activity over 100 days in samples from controls stored at ambient temperature (~22 °C), 4 °C and −20 °C. Samples stored at room temperature showed a fall to 94% original activity by day 4 (Fig. 5). Storage at 4 °C showed improved stability with 90% activity at day 21. Storage at −20 °C was optimal with 87% activity remaining at day 100.

LAL activity in DBS from 140 controls was 0.50–2.30 nmol/punch/h (2.5th–97.5th centile). Activity in 11 patients with CESD was <0.03 nmol/punch/h. Activity in 15 carriers was in the range 0.15–0.40 nmol/punch/h (Fig. 6).

4. Discussion and conclusions

The presence of other lipases in whole blood have the potential to interfere with the measurement of LAL in DBS [8]. Rosenbaum et al. screened ~40,000 compounds as potential inhibitors of LAL with the aim of using LAL as a therapeutic target for Niemann–Pick disease type C [9,10]. From this remarkable number they identified two compounds, compound 12 and 13, (3,4-disubstituted thiadiazole carbamates) subsequently renamed Lalistat 1 (compound 13) and Lalistat 2 (compound 12) as potent competitive inhibitors of LAL using human fibroblasts and purified human LAL. They demonstrated that both compounds had no effect on human pancreatic lipase and bovine milk lipoprotein lipase.

Conduritol-B-epoxide (CBE) is used as a specific inhibitor of β-glucocerebrosidase (GBA; EC 3.2.1.45) for the measurement of GBA


Fig. 5. LAL activity in DBS stored for up to 100 days at room temperature, 4 °C and –20 °C. Results are mean percentage residual activity from three controls.

in DBS to diagnose Gaucher disease [11]. By measuring total enzyme activity and activity in the presence of inhibitor it is possible to determine the enzyme of interest. Using the same principle our aim was to develop a method using Lalistat 2 as a specific inhibitor of LAL to allow the measurement of LAL in DBS.

We have demonstrated that Lalistat 2 is an effective inhibitor of recombinant human LAL in our assay with only 1% residual enzyme activity at a concentration of 1 μM. This was similar to the findings of Rosenbaum et al. [10]. We have also demonstrated that Lalistat 2 has no effect on human pancreatic lipase at inhibitor concentrations up to 10 μM, again similar to the findings of Rosenbaum et al. [10]. In our assay Lalistat 2 was shown to be a more effective inhibitor of LAL than Lalistat 1. The concentration of Lalistat 2 required for optimal inhibition was 1.5 μM with a pre-incubation period of 10 min proving to be more effective as reported by Rosenbaum et al. [10].

Stability of lysosomal enzymes in DBS varies depending on the enzyme concerned [12–15]. LAL shows a 6% fall in activity after 4 days at room temperature. With prompt transport of samples from referral laboratories LAL activity in DBS should be adequate for diagnostic purposes. Long term stability at −20 °C is good with 87% activity remaining at 100 days. Samples should be double-bagged with a dessicant to preserve optimal activity both in transit and long-term storage.

The method was assessed using DBS samples from 140 controls, 11 samples from patients with CESD and 15 carriers. LAL deficient samples show significantly reduced activity with results close to zero activity (<3% mean normal) in all 11 samples tested. Carriers show activity grouped neatly between normals and LAL deficient cases, with all results below the reference range (Fig. 6). Therefore the method differentiates clearly between normal activity, carriers and LAL deficient patients.

The development of a new method for the measurement of LAL in DBS has been made possible by use of the inhibitor Lalistat 2. The development of this new DBS method will allow screening for CESD and WD more readily in high risk populations with the potential for ERT in these patients.

Acknowledgements

References

[1] Assmann G, Seedorf U. Acid lipase deficiency: Wolman disease and Cholesterol ester storage disease. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 3551–72.

[2] Muntoni S, Wiebusch H, Jansen-Rust M, et al. Prevalence of Cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol 2007;27:1866–8.

[3] Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA 1999;281:249–54.

[4] vom Dahl S, Mengel E. Lysosomal storage diseases as differential diagnosis of hepatosplenomegaly. Best Pract Res Clin Gastroenterol 2010;24:619–28.

[5] Enns G, Balwani M, Deegan P, et al. Initial human experience with SBC-102, a recombinant enzyme replacement therapy in adults with lysosomal acid lipase deficiency abstracts. Mol Genet Metab 2012;105:S29.

[6] Du H, Cameron TL, Garger SJ, et al. Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice. J Lipid Res 2008;49(8):1646–57.

[7] Guy GJ, Butterworth J. Acid esterase activity in cultured skin fibroblasts and amniotic fluid cells using 4-methylumbelliferyl palmitate. Clin Chim Acta 1978;84:361–71.

[8] Mukherjee M. Human digestive and metabolic lipases – a brief review. J Mol Catal B: Enzym 2003;22:369–76.

[9] Rosenbaum AI, Rujoi M, Huang AY, et al. Chemical screen to reduce sterol accumulation in Niemann–Pick C disease cells identifies novel lysosomal acid lipase inhibitors. Biochim Biophys Acta 2009;1791:1155–65.

[10] Rosenbaum AI, Cosner CC, Mariani CJ, et al. Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann–Pick Type C disease therapeutics. J Med Chem 2010;53:5281–9.

[11] Olivova P, Cullen E, Titlow M, et al. An improved high-throughput dried blood spot screening method for Gaucher disease. Clin Chim Acta 2008;398:163–4.

[12] De Jesus VR, Zhang XK, Keutzer J, et al. Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage disorders. Clin Chem 2009;55:158–64.

[13] Legini E, Orsini JJ, Hung C, et al. Analysis of glucocerebrosidase activity in dry blood spots using tandem mass spectrometry. Clin Chim Acta 2011;412:343–6.

[14] Dajnoki A, Fekete G, Keutzer J, et al. Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometry. Clin Chim Acta 2010;411:1428–31.

[15] Dajnoki A, Muhl A, Fekete G, et al. Newborn screening for Pompe disease by measuring acid α-glucosidase activity using tandem mass spectrometry. Clin Chem 2008;54:1624–9.